GlaxoSmithKline is scheduled to make three poster presentations this week, including preclinical and early-stage data for its antibody-drug conjugate GSK2857916, or belantamab mafodotin, which targets B-cell maturation antigen in relapsed or refractory multiple myeloma. The presentations will be made at the ongoing meeting of the European Hematology Association in Amsterdam.
GlaxoSmithKline to present data on myeloma candidate
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.